New COPD drug 611 shows promise in chinese trial
NCT ID NCT06099652
First seen Nov 20, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study tested a new drug, 611, in 142 Chinese adults with moderate to severe COPD. The goal was to see if it improves lung function and is safe compared to a placebo over 16 weeks. Participants were aged 40 to 85 and had a history of smoking.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, 518020, China
-
Zhongshan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.